Precigen's (PGEN) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Precigen (NASDAQ:PGEN - Free Report) in a research note published on Thursday morning,Benzinga reports. The firm currently has a $6.00 target price on the biotechnology company's stock. HC Wainwright also issued estimates for Precigen's FY2027 earnings at $0.18 EPS, FY2028 earnings at $0.40 EPS and FY2029 earnings at $0.66 EPS.

Separately, JMP Securities reaffirmed a "market outperform" rating and set a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $7.00.

Precigen Stock Up 0.6 %

Shares of Precigen stock traded up $0.01 on Thursday, hitting $1.82. 1,022,455 shares of the company traded hands, compared to its average volume of 1,172,821. Precigen has a 12-month low of $0.65 and a 12-month high of $2.17. The company has a market cap of $535.16 million, a PE ratio of -3.31 and a beta of 1.58. The company has a 50-day moving average price of $1.62 and a 200 day moving average price of $1.16.

Remove Ads

Precigen (NASDAQ:PGEN - Get Free Report) last issued its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%. The firm had revenue of $1.19 million for the quarter, compared to the consensus estimate of $1.30 million. Equities research analysts anticipate that Precigen will post -0.32 EPS for the current year.

Institutional Investors Weigh In On Precigen

Several institutional investors and hedge funds have recently added to or reduced their stakes in PGEN. ProShare Advisors LLC grew its holdings in Precigen by 26.6% during the fourth quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company's stock valued at $58,000 after purchasing an additional 10,900 shares during the last quarter. Cetera Investment Advisers grew its stake in Precigen by 8.9% in the 4th quarter. Cetera Investment Advisers now owns 283,562 shares of the biotechnology company's stock valued at $318,000 after buying an additional 23,250 shares during the last quarter. Cary Street Partners Financial LLC bought a new position in Precigen in the 4th quarter worth $98,000. Bank of America Corp DE raised its holdings in Precigen by 11.6% in the 4th quarter. Bank of America Corp DE now owns 207,300 shares of the biotechnology company's stock worth $232,000 after acquiring an additional 21,626 shares during the period. Finally, BNP Paribas Financial Markets acquired a new position in Precigen during the 4th quarter worth $27,000. 33.51% of the stock is currently owned by institutional investors and hedge funds.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.